Myricx Pharma announces senior team expansion with appointment of CMO, and Heads of Biology and Bioinformatics

Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, has announced expansion of its senior team with the appointments of Zahid Bashir as Chief Medical Officer (CMO), Richard Rutter as Head of Biology and Francesco Falciani as Head of Bioinformatics.

With an initial focus in multiple oncology indications Myricx is developing a pipeline of novel proprietary inhibitors of human N-myristoyltransferases (NMT). The new appointments reflect the Company’s progress as it advances its lead programmes through preclinical development and IND-enabling studies, the company said.

Welcoming the new senior team members to the company Roberto Solari, PhD, Chairman, Chief Executive Officer and Co-founder said: “We are delighted to welcome Zahid, Richard and Francesco to the Myricx leadership team. As we progress our novel NMT inhibitors towards IND enabling studies and expand our proprietary pipeline of targeted cancer therapies for precision medicine their collective skills and experiences will be invaluable in strengthening our clinical development, biology and bioinformatics capabilities.”